World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
38782
World Ranking
8876
National Ranking
497

Overview

Hans-Joachim Schmoll is affiliated with Martin Luther University Halle-Wittenberg in Germany. Their research primarily focuses on medicine, with a significant emphasis on oncology. Within this field, they have contributed extensively to subfields such as oncology, pulmonary and respiratory medicine, pathology and forensic medicine, hepatology, and surgery.

The scientist's work addresses multiple topics relevant to cancer treatment and management. Key areas of research include colorectal cancer treatments and studies, colorectal cancer surgical treatments, gastric cancer management and outcomes, genetic factors in colorectal cancer, hepatocellular carcinoma treatment and prognosis, cancer treatment and pharmacology, and colorectal cancer screening and detection.

Hans-Joachim Schmoll's publications have appeared in several scientific journals. Frequent venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • JNCI Journal of the National Cancer Institute
  • European Journal of Cancer
  • ESMO Open

Recent notable papers authored or co-authored by Schmoll cover various oncological topics:

  • Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD (2020, Journal of Clinical Oncology)
  • Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer (2020, Journal of Clinical Oncology)
  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022, Leukemia)
  • MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer (2022, ESMO Open)
  • Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database (2021, JNCI Journal of the National Cancer Institute)

Hans-Joachim Schmoll collaborates with several researchers, among the most frequent co-authors are:

  • Aimery de Gramont
  • Qian Shi
  • Eric Van Cutsem
  • Richard M. Goldberg
  • Takayuki Yoshino

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

    Axel Grothey;Daniel Sargent;Richard M. Goldberg;Hans Joachim Schmoll

  • Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

    Daniel G. Haller;Josep Tabernero;Jean Maroun;Filippo De Braud

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Cyclooxygenase-2: a novel target for cancer chemotherapy?

    Wolfram Dempke;Christoph Rie;Axel Grothey;Hans Joachim Schmoll

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis

    Carsten Bokemeyer;Craig R. Nichols;Jean P. Droz;Hans J. Schmoll

  • Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials

    Cornelis J A Punt;Marc Buyse;Claus Henning Köhne;Peter Hohenberger

  • Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

    Hans Joachim Schmoll;Thomas Cartwright;Josep Tabernero;Marek P. Nowacki

  • Multidisciplinary Rectal Cancer Management : 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)

    Vincenzo Valentini;Cynthia Aristei;Bengt Glimelius;Bruce D. Minsky

  • Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

    C Bokemeyer;CC Berger;JT Hartmann;C Kollmannsberger

  • High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

    J Beyer;A Kramar;R Mandanas;W Linkesch

  • [Update S3-guideline "colorectal cancer" 2008].

    W. Schmiegel;A. Reinacher-Schick;D. Arnold;U. Graeven

  • Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

    Rainer Porschen;Hendrik Tobias Arkenau;Stephan Kubicka;Richard Greil

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Evaluation of long-term toxicity after chemotherapy for testicular cancer.

    C Bokemeyer;C C Berger;M A Kuczyk;H J Schmoll

  • Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer

    Claus Rödel;Gerhard. G. Grabenbauer;Thomas Papadopoulos;Werner Hohenberger

Frequent Co-Authors

Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Carsten Bokemeyer
Carsten Bokemeyer Universität Hamburg
Aimery de Gramont
Aimery de Gramont Grenoble Alpes University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
John R. Zalcberg
John R. Zalcberg Monash University
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA opens a variety of educational routes, many of which can be pursued online. For those interested in healthcare management, earning a health care administration degree can be a strategic move. These programs are often offered in an accelerated format, enabling students to quickly advance into roles managing hospitals or clinics.

Nursing remains a popular and flexible path. Some nursing schools that don't require teas test simplify the admissions process for aspiring nurses, creating a smoother entry into the profession. Already an RN? Bridge programs such as the rn to np bridge program allow registered nurses to become nurse practitioners efficiently, expanding both career scope and earning potential.

For those who prefer an administrative role, reputable medical billing and coding online schools offer foundational training with flexible schedules—often with financial aid—making this career accessible to more students. Whether you choose patient care or the administrative side of medicine, online pathways can help you reach your goals more efficiently.

Best Scientists Citing Hans-Joachim Schmoll

Trending Scientists

Recently Published Articles